Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases
Introduction Indications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1 This has been particularly useful for aneurysms that are difficult to treat via endosaccular or open approaches, such as pseudoaneurysms.2 Flow diversion, however, typicall...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Stroke: Vascular and Interventional Neurology |
| Online Access: | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.169 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387463081984000 |
|---|---|
| author | Michael T. Bounajem Anna Kuhn Ahmed Abdelsalam Gustavo Cortez Rawad Abbas Mubashir Pervez Hamzah Saei Shane Burke Ameer Hassan Adel Malek Varun Naragum Guilherme C. Dabus Stavropoula Tjoumakaris Pascal Jabbour Ricardo A. Hanel Robert M. Starke Juan Vivanco Suarez Santiago Ortega Gutierrez Mudassir Farooqui Mohamed Salem Brian Jankowitz Philipp Taussky Craig Kilburg Ajit S. Puri Ramesh Grandhi |
| author_facet | Michael T. Bounajem Anna Kuhn Ahmed Abdelsalam Gustavo Cortez Rawad Abbas Mubashir Pervez Hamzah Saei Shane Burke Ameer Hassan Adel Malek Varun Naragum Guilherme C. Dabus Stavropoula Tjoumakaris Pascal Jabbour Ricardo A. Hanel Robert M. Starke Juan Vivanco Suarez Santiago Ortega Gutierrez Mudassir Farooqui Mohamed Salem Brian Jankowitz Philipp Taussky Craig Kilburg Ajit S. Puri Ramesh Grandhi |
| author_sort | Michael T. Bounajem |
| collection | DOAJ |
| description | Introduction Indications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1 This has been particularly useful for aneurysms that are difficult to treat via endosaccular or open approaches, such as pseudoaneurysms.2 Flow diversion, however, typically requires dual antiplatelet therapy (DAPT), which can contribute to greater morbidity particularly in patients with ruptured aneurysms or other comorbidities.3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4 In light of this reduced thrombogenicity, there have been reports of early transition to single antiplatelet therapy (SAPT), or other variations on DAPT, in patients treated with PED Shield. We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagic outcomes, utilized in patients with aneurysms treated with PED Shield. Methods Factors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected. Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stent thrombosis were also recorded. Results One‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured. One hundred and sixty‐two patients had a single device placed, while the remaining had two devices placed. Three patients were maintained on SAPT post‐procedurally (aspirin or clopidogrel), with two additional patients treated with SAPT plus an anticoagulant for other purposes. One hundred and seventy‐two patients were maintained on DAPT, most commonly aspirin/clopidogrel (115), followed by aspirin/ticagrelor (40), and aspirin/prasugrel (16). Seven patients had strokes of any kind, three of which were unrelated to the treatment territory, and two of the remaining 4 were non‐compliant with antiplatelet therapy. One patient had a new intraparenchymal hemorrhage, but no appreciable deficit. Of the 135 patients with 6‐month follow‐up, 77 had complete aneurysm occlusion, and 116 demonstrated no in‐stent thrombosis. Conclusion We demonstrate herein the similar safety profile and efficacy of PED Shield with varying antiplatelet regimens, including SAPT in isolated cases. |
| format | Article |
| id | doaj-art-5b3ea9e9d88442ccb81f5ce5c306d5c2 |
| institution | Kabale University |
| issn | 2694-5746 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke: Vascular and Interventional Neurology |
| spelling | doaj-art-5b3ea9e9d88442ccb81f5ce5c306d5c22025-08-20T03:53:51ZengWileyStroke: Vascular and Interventional Neurology2694-57462023-11-013S210.1161/SVIN.03.suppl_2.169Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 casesMichael T. Bounajem0Anna Kuhn1Ahmed Abdelsalam2Gustavo Cortez3Rawad Abbas4Mubashir Pervez5Hamzah Saei6Shane Burke7Ameer Hassan8Adel Malek9Varun Naragum10Guilherme C. Dabus11Stavropoula Tjoumakaris12Pascal Jabbour13Ricardo A. Hanel14Robert M. Starke15Juan Vivanco Suarez16Santiago Ortega Gutierrez17Mudassir Farooqui18Mohamed Salem19Brian Jankowitz20Philipp Taussky21Craig Kilburg22Ajit S. Puri23Ramesh Grandhi24University of Utah Utah United StatesUniversity of Massachusetts Massachusettsssachusetts United StatesUniversity of Miami Florida United StatesBaptist Medical Center Jacksonville Florida United StatesThomas Jefferson University Pennsylvania United StatesBaptist Medical Center Jacksonville Florida United StatesUniversity of Texas Rio Grande Valley Texas United StatesTufts Medical Center Massachusettsssachusetts United StatesUniversity of Texas Rio Grande Valley Texas United StatesTufts Medical Center Massachusettsssachusetts United StatesUniversity of Massachusetts Massachusettsssachusetts United StatesMiami Neuroscience Institute Florida United StatesThomas Jefferson University Pennsylvania United StatesThomas Jefferson University Pennsylvania United StatesBaptist Medical Center Jacksonville Florida United StatesUniversity of Miami Florida United StatesUniversity of Iowa Iowa United StatesUniversity of Iowa Iowa United StatesUniversity of Iowa Iowa United StatesUniversity of Pennsylvania Pennsylvania United StatesUniversity of Pennsylvania Pennsylvania United StatesBeth Israel Deaconess Medical Center Massachusettsssachusetts United StatesUniversity of Utah Utah United StatesUniversity of Massachusetts Massachusettsssachusetts United StatesUniversity of Utah Utah United StatesIntroduction Indications for flow diversion for the treatment of cerebral aneurysms have increased remarkably in recent years.1 This has been particularly useful for aneurysms that are difficult to treat via endosaccular or open approaches, such as pseudoaneurysms.2 Flow diversion, however, typically requires dual antiplatelet therapy (DAPT), which can contribute to greater morbidity particularly in patients with ruptured aneurysms or other comorbidities.3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4 In light of this reduced thrombogenicity, there have been reports of early transition to single antiplatelet therapy (SAPT), or other variations on DAPT, in patients treated with PED Shield. We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagic outcomes, utilized in patients with aneurysms treated with PED Shield. Methods Factors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected. Follow‐up data including aneurysm thromboembolic complication, hemorrhagic complication, new neurological deficit, aneurysm occlusion, and in‐stent thrombosis were also recorded. Results One‐hundred and eighty patients were included in analysis, 18 of which were acutely ruptured. One hundred and sixty‐two patients had a single device placed, while the remaining had two devices placed. Three patients were maintained on SAPT post‐procedurally (aspirin or clopidogrel), with two additional patients treated with SAPT plus an anticoagulant for other purposes. One hundred and seventy‐two patients were maintained on DAPT, most commonly aspirin/clopidogrel (115), followed by aspirin/ticagrelor (40), and aspirin/prasugrel (16). Seven patients had strokes of any kind, three of which were unrelated to the treatment territory, and two of the remaining 4 were non‐compliant with antiplatelet therapy. One patient had a new intraparenchymal hemorrhage, but no appreciable deficit. Of the 135 patients with 6‐month follow‐up, 77 had complete aneurysm occlusion, and 116 demonstrated no in‐stent thrombosis. Conclusion We demonstrate herein the similar safety profile and efficacy of PED Shield with varying antiplatelet regimens, including SAPT in isolated cases.https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.169 |
| spellingShingle | Michael T. Bounajem Anna Kuhn Ahmed Abdelsalam Gustavo Cortez Rawad Abbas Mubashir Pervez Hamzah Saei Shane Burke Ameer Hassan Adel Malek Varun Naragum Guilherme C. Dabus Stavropoula Tjoumakaris Pascal Jabbour Ricardo A. Hanel Robert M. Starke Juan Vivanco Suarez Santiago Ortega Gutierrez Mudassir Farooqui Mohamed Salem Brian Jankowitz Philipp Taussky Craig Kilburg Ajit S. Puri Ramesh Grandhi Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases Stroke: Vascular and Interventional Neurology |
| title | Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases |
| title_full | Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases |
| title_fullStr | Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases |
| title_full_unstemmed | Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases |
| title_short | Abstract 169: Antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters: a series of 180 cases |
| title_sort | abstract 169 antiplatelet regimens after pseudoaneurysm embolization with phosphorylcholine coated flow diverters a series of 180 cases |
| url | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_2.169 |
| work_keys_str_mv | AT michaeltbounajem abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT annakuhn abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT ahmedabdelsalam abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT gustavocortez abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT rawadabbas abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT mubashirpervez abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT hamzahsaei abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT shaneburke abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT ameerhassan abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT adelmalek abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT varunnaragum abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT guilhermecdabus abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT stavropoulatjoumakaris abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT pascaljabbour abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT ricardoahanel abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT robertmstarke abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT juanvivancosuarez abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT santiagoortegagutierrez abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT mudassirfarooqui abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT mohamedsalem abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT brianjankowitz abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT philipptaussky abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT craigkilburg abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT ajitspuri abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases AT rameshgrandhi abstract169antiplateletregimensafterpseudoaneurysmembolizationwithphosphorylcholinecoatedflowdivertersaseriesof180cases |